Despite worsening heart failure (HF) being extremely common, expensive, and associated
with substantial risk of death, there remain no dedicated clinical practice guidelines for the …

Heart failure with reduced ejection fraction (HFrEF) is a complex and progressive clinical
condition characterized by dyspnea and functional impairment. HFrEF has a high burden of …

Recent trials have shown the efficacy of new drugs for the medical therapy of heart failure
with reduced ejection fraction (HFrEF). Sodium-glucose cotransporter 2 inhibitors (SGLT2is) …

Since the inception of the Canadian Cardiovascular Society heart failure (HF) guidelines in
2006, much has changed in the care for patients with HF. Over the past decade, the HF …

Due to remarkable improvements in heart failure (HF) management over the last 30 years, a
significant reduction in mortality and hospitalization rates in HF patients with reduced …

Heart failure (HF) is a progressive disease characterized by variable durations of
symptomatic stability often punctuated by episodes of worsening despite continued therapy …

Background: Epidemiology of patients with worsening heart failure and reduced ejection
fraction (HFrEF) in the real-world setting is not well described. Objectives: The purpose of …

Heart failure (HF) with preserved ejection fraction (HFpEF) is the most common form of HF.
Among elderly women, HFpEF comprises more than 80% of incident HF cases. Adverse …

The advent of newly available medical therapies for heart failure with reduced ejection
fraction (HFrEF) has resulted in many potential therapeutic combinations, increasing …

Heart failure (HF) is highlighted by its burdening symptom-limited exercise capacity and
recurrent hospitalizations. Despite substantial advances regarding disease-modifying drugs …